The epidemiology and clinical presentation of seropositive neuromyelitis optica spectrum disorder in a <scp>US</scp> population
Seropositive NMOSD incidence is higher in our cohort than many contemporary studies. Women and those identifying as Asian or Pacific Islander, Black, and Hispanic shoulder the highest burden of disease. Clinical onset with short-segment myelitis underscores the need for serum aquaporin-4 IgG testing in acute myelitis presentations.
Authors
- Stefan Sillau (ORCID: https://orcid.org/0000-0002-8691-3139)
- Carlos Eduardo Vervloet Sollero (ORCID: https://orcid.org/0000-0001-8538-6552)
- Kelli M. Money (ORCID: https://orcid.org/0000-0002-7432-5882)
- Jeffrey L. Bennett (ORCID: https://orcid.org/0000-0002-3346-1394)
- Aaron Carlson (ORCID: https://orcid.org/0000-0001-7520-7864)
- Andrew B. Wolf (ORCID: https://orcid.org/0000-0002-1406-4107)
- Barrie Schmitt
- Kavita V. Nair (ORCID: https://orcid.org/0009-0009-0201-1495)
- Amanda L. Piquet (ORCID: https://orcid.org/0000-0001-7349-6455)
Institutions
- University of Colorado Health (US)
- Memorial Hospital (US)
- University of Colorado Anschutz Medical Campus (US)
- University of Rochester (US)
- University of Montana (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Annals of Clinical and Translational Neurology
- Published
- 2024-12-21
- DOI
- https://doi.org/10.1002/acn3.52268
- Citations
- 4
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.70
Funders
- Pharmaceutical Research and Manufacturers of America Foundation
- Amgen
- Bristol-Myers Squibb
- AstraZeneca
- Sanofi
- Biogen
- Alexion Pharmaceuticals
- TG Therapeutics
- BeiGene
- Horizon Therapeutics
- National Institutes of Health
- Genentech
- EMD Serono
- Chugai Pharmaceutical